rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PHAR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Pharming at Jefferies Global Healthcare Conference: pipeline gains
      17h agoInvesting.comPHARJEF
      MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.

      Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in February 2027Marks another step in Pharming’s strategy to expand Joenja across age groups and international markets Leiden, the Netherlands, November 6, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announce

      Nov 6Yahoo FinancePHAR
      Pharming: 3 Key Takeaways for Long-Term Investors | The Motley Fool

      A rare-disease player with a stabilized core product is now targeting a market 26 times larger, fueled by cash generation that needs no external financing.

      Nov 4The Motley FoolPHAR
      Pharming Group (PHGUF) Q3 2026 Earnings Call Highlights: Revenue Jumps 21% as Rucanest Rebounds ...
      Oct 28Yahoo FinancePHAR
      Oppenheimer reiterates Pharming Group stock rating at Outperform
      Oct 28Investing.comPHAR
      Pharming Group (ENXTAM:PHARM) Stock Faces A Q3 Earnings Valuation Gap
      Oct 28Yahoo FinancePHAR
      Pharming (PHAR) Q3 2026 Earnings Call Transcript
      Oct 27The Globe and MailPHAR
      Pharming Group Q3 Earnings Call Highlights
      Oct 27Yahoo FinancePHAR
      Pharming Q3 2026 slides: dual growth drives 21% revenue beat
      Oct 27Investing.comPHAR
      Pharming Q3 2026 Earnings Call Transcript
      Oct 27BenzingaPHAR
      Earnings call transcript: Pharming Group tops Q3 2026 revenue forecasts
      Oct 27Investing.comPHAR
      Why is Pharming stock climbing today?
      Oct 27Investing.comPHAR
      Pharming Q3 Earnings, Revenue Increase
      Oct 27Yahoo FinancePHAR
      Pharming Q3 operating profit jumps 89%, narrows 2026 revenue outlook
      Oct 27Investing.comPHAR
      Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
      Oct 27Yahoo FinancePHAR
      Pharming stock jumps on Q3 revenue beat
      Oct 22Investing.comPHAR
      Pharming Group announces third quarter 2026 revenues above market expectations
      Oct 22Yahoo FinancePHAR
      Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

      First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulationLeniolisib was well-tolerated, with benefits observed across multiple measures of immune dysregulation, including improvement in lymphoproliferation and positive trends in lung and liver disease markersAll participants who completed the study elected to continue receiving treatment in a long-term extension study Leiden, the Net

      Oct 14Yahoo FinancePHAR
      Analysts Are Bullish on These Healthcare Stocks: Pharming Group (PHAR), Inventiva (IVA)

      Detailed price information for Inventiva S.A. ADR (IVA-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailIVAPHAR
      Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes (NASDAQ:PHAR)
      Sep 30Seeking AlphaPHAR
      Pharming Appoints Leverne Marsh, Kenneth Lynard as Co-CEOs

      Pharming Group (PHAR) has appointed Chief Commercial Officer Leverne Marsh and Chief Financial Offic

      Sep 29Yahoo FinancePHAR
      Pharming shares fall after CEO steps down over strategy dispute
      Sep 29Investing.comPHAR
      Pharming announces CEO transition
      Sep 29Yahoo FinancePHAR
      Pharming CEO Fabrice Chouraqui steps down immediately
      Sep 29Investing.comPHAR
      Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

      If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or moreDecision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kgPDUFA target action date of January 30, 2027 Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration

      Sep 25Yahoo FinancePHAR
      Canaccord reiterates Pharming stock rating on positive trial data
      Sep 23Investing.comPHAR
      Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

      Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results from a Phase II trial of leniolisib in CVID in Q4 2026 Leiden, the Netherlands, September 22, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that a late-breaking abstract highlighti

      Sep 22Yahoo FinancePHAR
      Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
      Sep 21Yahoo FinancePHAR
      Pharming Group (PHAR) Expands Joenja’s Pediatric Label. Can Growth Offset RUCONEST Weakness?

      Pharming Group N.V. (NASDAQ:PHAR) announced on September 11 that the U.S. Food and Drug Administration approved Joenja for children aged 4–11 with activated PI3K delta syndrome, or APDS, who weigh at least 27 kilograms. APDS disrupts immune function. The new 40 mg and 50 mg tablet strengths expand dosing options for Joenja, or leniolisib. The […]

      Sep 16Yahoo FinancePHAR
      Pharming Group N.V. (PHAR) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow
      Sep 14Seeking AlphaPHAR
      Pharming Group N.V. (PHAR) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow (NASDAQ:PHAR) 2026-09-14
      Sep 14Seeking AlphaPHAR
      FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

      FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are expected to be available in October Leiden, the Netherlands, September 11, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental

      Sep 11Yahoo FinancePHAR
      Pharming: Faltering Rare-Disease Franchise With Two Potentially Transformative Late-Stage Assets
      Sep 9Seeking AlphaPHAR
      Pharming Group to participate in September investor conferences

      Leiden, the Netherlands, September 9, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the month of September: H.C. Wainwright 28th Annual Global Investment Conference, New York, September 14, 2026Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 14 at 09:30 EDT/15:30 CEST. A live webcast and replay of the presentation will be made available in

      Sep 8Yahoo FinancePHAR

      This is the newest page. Registered accounts read further back.